Yüklüyor......
Hexosamine Biosynthetic Pathway (HBP) inhibition leads to AML cell differentiation and cell death.
Treatment for Acute myeloid leukemia (AML) has remained unchanged for past 40 years. Targeting cell metabolism is a promising avenue for future cancer therapy. We found that enzymes involved in metabolic hexosamine biosynthetic pathway (HBP) are increased in AML patients. Inhibiting GFAT (the rate l...
Kaydedildi:
| Yayımlandı: | Mol Cancer Ther |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6168390/ https://ncbi.nlm.nih.gov/pubmed/30082471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0426 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|